Docket No. PRD-2009-USPCT1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peeters et al.

Int'l Appln. No.: PCT/EP2003/011792

Serial No. : Unassigned

Art Unit: Unassigned

Filed

: I.A. 23.10.2003

Examiner: Unassigned

For

: CRH RESPONSIVE GENES IN CNS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

April 27, 2005

Laura A. Donnelly (Name of applicant, assignee, or Registered Representative)

/Laura A. Donnelly/
(Signature)

April 27, 2005
(Date of Signature)

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

, is a

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information X Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [the first or second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-П the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is

accompanied by one of:

(attached); or	
(actached); Of Please charge Deposit Account No. 10-	
0750/ / the fee of \$180.00 as set forth	
in §1.17(p).	
In accordance with §1.97(d), this Information	
Disclosure Statement is being filed after the mailing date of	
either a Final Action under §1.113 or a Notice of Allowance	
under §1.311 but before the payment of the Issue Fee.	
Applicant(s) hereby petition(s) for consideration of this	
Information Disclosure Statement. Included are: Statement in	
Accordance with §1.97(e) as set forth below and the fee of	
\$180.00 as set forth in §1.17(p).	
○ Copies of each of the references listed on the	
—	
attached Form PTO-1449 are enclosed herewith.	
Copies of references listed on the attached Form PTO-	
1449 are enclosed herewith EXCEPT THAT:	
In view of the voluminous nature of references	
[list as appropriate], and the likelihood that	
these references are available to the Examiner,	
copies are not enclosed herewith.	
If any of the foregoing publications are not	
available to the Examiner, Applicant will	
endeavor to supply copies at the Examiner's	
request.	
Copies of only foreign patent documents and non-	
patent literature are enclosed in accordance with 37 CFR 1.98	
(a) (2).	
•	

10/533054 JC20 R PCT/PTO 27 APR 2005

$oxed{igwedge}$ There are no listed	references which are not in the
English language.	
The relevance of tho not in the English language is	se listed references which are as follows:
	of search report(s) from on(s), which are listed on the 609 D.
Attached are the folpatent applications which may listed on the attached Submiss	
Please charge any deficie	ency or credit any overpayment to
	D-2009-USPCT1/LAD. This form is
submitted in triplicate.	
	Respectfully submitted,
	/Laura A. Donnelly/ Laura A. Donnelly Reg. No. 38,435 Attorney for Applicants
Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003	

(732) 524-1729 DATED: April 27, 2005





Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control purple.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

0	a collection of information unless it displays a	Valid OWR COurtoffinder.
	Application Number	Unassigned 3U 24
	Filing Date	April 27, 2005
	First Named Inventor	Peeters et al.
	Group Art Unit	Unassigned
ı	Examiner Name	Unassigned
	Attorney Docket Number	PRD-2009-USPCT1

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines. Name of Patentee or Applicant Kind Code² Examiner Cite where relevant passages or of Cited Document of Cited Document Initials relevant figures appear (if known) Number No.1 mm-dd-yyyy

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite mm-dd-yyyy Applicant of Cited Document figures appear KindCode⁵ Office³ Number⁴ No.1

Examiner	Date	
Signature	Considered	
APPARA A 444 A	DED 000 D .	the state of the s

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays a	I Valle OMB Charlot Hunder.
Application Number	Unassigned 5 U 5 4
Filing Date	April 27, 2005
First Named Inventor	Peeters et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	PRD-2009-USPCT1

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Bonaldo et al., Abstract XP-002249222, "Normalization and subtraction: two approaches to facilitate gene discovery", Genome Res., Vol. 9, pp. 791-806 (1996).	
		Brunson et al., Abstract XP-001153651, "Corticotropin Releasing Hormone Downregulates CRF ₁ Binding and Induces CRF ₁ Gene Expression in Hippocampus and Cortex of the Immature Rat".	
		Da Costa et al., "Region-specific immediate-early gene expression following the administration of cortico-tropin-releasing hormone in virgin and lactating rats", Elsevier Science B.V., Vol. 770, pp. 151-162 (1997).	
		Bakshi et al., "Corticotropin-Releasing Hormone and Animal Models of Anxiety: Gene-Environment Interactions", Society of Biological Psychiatry, Vol. 48, pp. 1175-1198 (2000).	
		van Gaalen et al., "Effects of transgenic overproduction of CRH on anxiety-like behaviour", European Journal of Neuroscience, Vol. 15, pp. 2007-2015 (2002).	
		Florian Holsboer, M.D., Ph.D., "The Corticosteroid Receptor Hypothesis of Depression", American College of Neuropsychopharmacology, Vol. 23, No. 5, pp. 477-501 (2000).	

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

JC20 Rec'd PCT TO 2 7 APR 2005

SUBMISSION UNDER MPEP 609 D Application Number Filing Date April 27, 2005 First Named Inventor Peeters et al. Group Art Unit Unassigned Examiner Name Unassigned Attorney Docket Number PRD-2009-USPCT1

		U.S. PA	TENT DOCUMENTS	T 15114	
	Cite	Name of Patentee or Applicant of Cited Document	U.S. Patent Document .		
Examiner Initials			Number	Kind Code ² (if known)	Pages, Columns, Lines, where relevant passages o relevant figures appear
	.	· · · · · · · · · · · · · · · · · · ·			
	-				
	-				
·					
-					

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages or relevant figures Name of Patentee or Examiner Cite T⁶ Applicant of Cited Document KindCode5 appear Office³ Number⁴ Initials OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published T² Examiner Cite Initials* International Search Report dated February 2, 2004 for related International Application No. PCT/EP2003/011792

Date

Considered

Examiner

Signature